Bryxta 400mg Injection

The following conditions are approved for injection treatment with Bryxta 400mg:

• Advanced non-small-cell lung cancer
• Liver Cancer- Hepatocellular carcinoma
• Persistent, recurrent, or metastatic breast cancer
• Metastatic cervical cancer
• Advanced kidney cancer
• Metastatic colorectal cancer
• Glioblastoma multiforme (brain cancer)
• Ovary, cervical, fallopian tube, or primary peritoneal cancer.
  

Bryxta 400mg Injection may cause some serious and unwanted side effects. This requires immediate medical attention; otherwise, it can also lead to a higher risk. Do not forget to discuss the risks and benefits of this medication with your doctor.

• Bleeding gums 
• Chest pain 
• Sore throat 
• Fever 
• Dizziness 
• Irregular heartbeat 
• Loss of appetite 
• Body pain 
• Runny nose 
• Vomiting 
• Diarrhea 
  
• Unusual bleeding 
• High blood pressure 

Bryxta 400mg Injection will be given intravenously by your doctor or nurse. After the dilution, the infusion must be injected immediately. The 400 mg injection of bevacizumab according to recommendations by your physician. Make sure to take this injection in accordance with your dose regimen and avoid mishandling this medication. Your doctor can provide emergency medical care in the event of an overdose.

• Bryxta 400mg is a  a  recombinant humanized monoclonal antibody is  for treating a variety of advanced malignancies as a targeted therapy.
• It works by attaching itself specifically to the protein known as vascular endothelial growth factor A (VEGF-A), which is found in the body's blood and lymph arteries.
• It prohibits VEGF-A from binding with its receptors. This additionally blocks  of blood vessels which supply the tumor with nutrients and oxygen. As a result, it slows the rate at which cancer progresses.
  

​Bevacizumab 400mg Injection is given by your doctor or nurse. If you miss an appointment for a scheduled dose of this medicine, contact your doctor immediately.​

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices*—plus *special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

• Vaidyanathan, A., Vana, P., Joshi, N., Sourav, B., Bhargava, P., John, G., Ramaswamy, A., & Ostwal, V. (2025). Real-world evidence for comparative outcomes between innovator and biosimilar bevacizumab in advanced colorectal cancers. South Asian Journal of Cancer, 13(4), 296–299. https://doi.org/10.1055/s-0045-1804535
• Kasliwal, R. S., Reddy, P., Maharaj, N., Shah, H., Nayak, M., Dhoot, D., & Jain, S. (2023). Comparison of efficacy and safety of a bevacizumab biosimilar, in combination with chemotherapies, in nonresectable metastatic colorectal cancer and advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, Phase III study. South Asian Journal of Cancer, 13(1), 66–76. https://doi.org/10.1055/s-0043-1774403
• Sinha, S. D., Biswas, G.,Bheemareddy, B. R., Dubashi, B., Rangwala, R., Pandey, A. K., & Venkitaraman, R. (2023). A real-world study of safety, immunogenicity and efficacy of Bevacizumab in patients with solid malignancies: A Phase IV, post-marketing study in India. Cancer Informatics, 22, 11769351231177277. https://doi.org/10.1177/11769351231177277